Abstract
The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.
MeSH terms
-
Animals
-
Cerebrovascular Disorders / drug therapy*
-
Clinical Trials as Topic
-
Drug Discovery
-
Humans
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Purinergic P2Y Receptor Antagonists / therapeutic use*
-
Receptor, PAR-1 / antagonists & inhibitors
-
Risk Assessment
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Purinergic P2Y Receptor Antagonists
-
Receptor, PAR-1